Artefill for the Treatment of HIV-associated Facial Lipoatrophy

Artefill is an injectable facial filler device that is currently approved by the FDA for the correction of nasolabial folds. This study seeks to examine the use of Artefill in the treatment of HIV associated facial lipoatrophy. Facial lipoatrophy (facial fat loss) related to HIV is a stigmatizing condition characterized by loss of facial fat, most notably in the cheeks and temples.

Study Overview

• Status: Completed
• Conditions: HIV-facial Lipoatrophy
• Intervention / Treatment: Drug: Artefill dermal filler

Detailed Description

The objectives of this study are:

To evaluate the long-term safety of Artefill injection volumes that are three to four times greater (i.e. up to 30 ml) than the volume indicated in the FDA approved product label (i.e. 8.9 ml)subjects with HIV.

To evaluate any adverse events associated with the use of Artefill. To evaluate the Quality of Life and body image benefit from Artefill treatment in patients with lipoatrophy.

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Vero Beach, Florida, United States, 32960
      • Whole Family Health Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 78 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject is male or female between 18-80 years of age inclusive at the time of signing the informed consent.
2. Subject desires treatment for facial volume loss.
3. Subject has HIV infection with moderated to severe facial lipoatrophy based on the Modified James Scale grades II-IV.
4. Subject has viral load <400 copies/mL.
5. Subject has CD4 lymphocyte counts >200/mm.
6. Subject has documented negative Artefill skin test or has received treatment with Artefill in the past without evidence of hypersensitivity reaction.
7. Subject is willing to withhold additional aesthetic implant therapies (eg, other soft tissue fillers such as Restylane, silicone, Radiesse, Sculptra or implants such as Gortex, Silastic, etc) for the duration of the study.

Exclusion Criteria:

1. Subject has any skin pathology, inflammatory skin disease, or condition that could interfere with the evaluation of the treatment areas.
2. Subject has a history of systemic granulomatous diseases (sarcoid, Wegeners, etc) or connective tissue disease (lupus, dermatomyositis, ect)
3. Subject has history of keloid formation or hypertrophic scarring.
4. Subject has a history of malignancy (other than skin cancer) within 12 months of enrollment. 5.Subject has been treated with systemic corticosteroids(eg, prednisone) or interferon within 1 month prior to study enrollment

6. Subject has thrombocytopenia or a bleeding diathesis. 7. Subject is pregnant, planning to become pregnant, or breastfeeding. 8..Subject has been treated with any of the following within the time intervals specified prior to start of their participation in the study: Bovine collagen-6 months Hyaluronic acid-6 months Calcium hydroxylapatite-6 months Polyacrylamide-at any time Polylactic acid- 6 months Permanent implant grafts at any time. 9. Subject has severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies.

10. Subject has a known hypersensitivity to lidocaine. 11. Subject has a history of allergies to any bovine collagen products. 12. Subject is undergoing or planning to undergo desensitization injections to meat products.

13. Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.

14. Subject has substance abuse, depression, or other issues that, according to the investigator's judgment, would interfere with conduct of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Artefill; Four treatment visits using Artefill dermal filler	Drug: Artefill dermal filler; Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.; Other Names: polymethylmethacrylate (PMMA)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Artefill for the Treatment of HIV-Associated Facial Lipoatrophy	To evaluate the effectiveness of Artefill injections as a long-term treatment for human immunodeficiency virus (HIV)-associated facial lipoatrophy over 36 months by assessing changes in the Global Aesthetic Improvement Scale (GAIS) based on pre/post intervention photography.	36 months
Artefill for the Treatment of HIV-associated Facial Lipoatrophy	To evaluate the safety of Artefill injections as a long-term treatment for HIV-associated facial lipoatrophy over 36 months by monitoring the incidence of adverse events.	36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Artefill for the Treatment of HIV-Associated Facial Lipoatrophy	To evaluate the effectiveness of Artefill injections as a long-term treatment for HIV-associated facial lipoatrophy over 36 months by assessing changes in the Modified James Scale grade based on assessment of pre/post intervention photography by 2 blinded physicians.	36 months
Artefill for the Treatment of HIV-associated Facial Lipoatrophy	To evaluate the effects of Artefill injections on HIV-associated facial lipoatrophy as evidenced by the subject satisfaction questionnaire.	36 months
Artefill for the Treatment of HIV-associated Facial Lipoatrophy	To evaluate the effects of Artefill injections on the subject's psychological well-being using the Medical Outcomes study-HIV (MOS-HIV)assessment.	36 months
Artefill for the Treatment of HIV-associated Facial Lipoatrophy	To evaluate the acceptability and tolerability of Artefill injections as reported by subjects.	36 months

Collaborators and Investigators

• Sponsor: Gerald Pierone, Jr. M.D.
• Collaborators: Suneva Medical, Inc.
• Investigators: Principal Investigator: Gerald Pierone, Jr., M.D, AIDS Research and Treatment Center of the Treasure Coast

Study record dates

Study Major Dates

• Study Start: December 1, 2013
• Primary Completion (Actual): November 1, 2019
• Study Completion (Actual): November 1, 2019

Study Registration Dates

• First Submitted: December 5, 2013
• First Submitted That Met QC Criteria: December 9, 2013
• First Posted (Estimate): December 12, 2013

Study Record Updates

• Last Update Posted (Actual): July 15, 2020
• Last Update Submitted That Met QC Criteria: July 13, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: HIV; Facial lipoatrophy
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Skin Diseases; Disease Attributes; Lipid Metabolism Disorders; Skin Diseases, Metabolic; Lipodystrophy; Facies; Physiological Effects of Drugs; Vasodilator Agents; Protective Agents; Antimutagenic Agents; Polymethyl Methacrylate
• Other Study ID Numbers: ARTCTC-01-001